Ellipses Launches Pioneering Clinical Trial Programme in Middle East | Morningstar

December 23, 2024

Ellipses Pharma launches first large-scale Phase 1/2 oncology trial in UAE for EP0031/A400, a next-gen RET inhibitor targeting RET-altered tumors, with trials underway in the US, Europe, and China.

Related Clinical Trials

A Study of EP0031 in Patients With Advanced RET-altered Malignancies

A Study of KL590586 in Patients With Advanced Solid Tumors

Highlighted Terms

Cleveland Clinic Emirates Drug Establishment Kelun Pharmaceutical NCT05265091 Tawam Hospital M42 Ellipses Pharma Limited thyroid cancer NCT05443126 non-small cell lung cancer U.S. Food and Drug Administration Kelun Biotech EP0031/A400

Related News

morningstar.com

Ellipses Launches Pioneering Clinical Trial Programme in Middle East | Morningstar

Ellipses Pharma launches first large-scale Phase 1/2 oncology trial in UAE for EP0031/A400, a next-gen RET inhibitor targeting RET-altered tumors, with trials underway in the US, Europe, and China.